This study presents a unique three-pronged approach that combines mRNA-based CAR T cells, multi-targeting of GBM-associated receptors, and NTR surgery as a new strategy to combat tumor heterogeneity and antigen loss, limit postoperative relapse, as well as achieve safe durable remissions. Here, NTSR1 is linked to glioblastoma.